scholarly article | Q13442814 |
P2093 | author name string | Michael E Phelps | |
David B Stout | |||
Magnus Dahlbom | |||
Nagichettiar Satyamurthy | |||
Jorge R Barrio | |||
Marc A Seltzer | |||
Richard Sparks | |||
Shamim A Jahan | |||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1233-1236 | |
P577 | publication date | 2004-07-01 | |
P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
P1476 | title | Radiation dose estimates in humans for (11)C-acetate whole-body PET. | |
P478 | volume | 45 |
Q37209479 | 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. |
Q38098441 | 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients |
Q37214513 | 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients |
Q90309705 | Astrocyte metabolism in multiple sclerosis investigated by 1-C-11 acetate PET |
Q33523536 | Biodistribution and radiation dosimetry of [(11)C]choline: a comparison between rat and human data. |
Q35556123 | Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine - a review |
Q60305515 | Current Imaging Techniques for Lymph Node Staging in Prostate Cancer: A Review |
Q40094312 | Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study |
Q39512219 | Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines? |
Q35633633 | Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma. |
Q40364894 | Future direction of renal positron emission tomography |
Q43253704 | Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation |
Q34619649 | Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model |
Q36129937 | Molecular imaging of prostate cancer: PET radiotracers |
Q47100803 | Normal Uptake of 11C-Acetate in Pancreas, Liver, Spleen, and Suprarenal Gland in PET. |
Q38606252 | Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET. |
Q35288176 | PET Imaging of Prostate Cancer Using C-Acetate |
Q39003086 | PET Tracers Beyond FDG in Prostate Cancer. |
Q46704395 | PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective |
Q36308766 | PET/CT in prostate cancer: non-choline radiopharmaceuticals |
Q37518179 | Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of (18)F-fluoroacetate ((18)F-FACE) in non-human primates |
Q33890153 | Positron emission tomography (PET) in primary prostate cancer staging and risk assessment |
Q37127700 | Prediction of all-cause death using (11)C-hydroxyephedrine positron emission tomography in Japanese patients with left ventricular dysfunction |
Q34448553 | Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline |
Q34062324 | Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence |
Q38715665 | Radiation Dosimetry of Whole-Body Dual-Tracer 18F-FDG and 11C-Acetate PET/CT for Hepatocellular Carcinoma. |
Q61449123 | Radiation dosimetry of [Ga]PSMA-11 in low-risk prostate cancer patients |
Q37217782 | Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies |
Q38058333 | The clinical use of PET with (11)C-acetate. |
Q36113718 | The metabolic fate of acetate in cancer |
Q37094838 | Visualizing pancreatic beta-cell mass with [11C]DTBZ. |
Q53501793 | [1-(11)C]acetate uptake is not increased in renal cell carcinoma. |
Q39985717 | [11C] acetoacetate utilization by breast and prostate tumors: a PET and biodistribution study in mice. |
Q53527477 | [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. |
Search more.